WO2015018528A1 - Il-15 and il-15raplha sushi domain based modulokines - Google Patents
Il-15 and il-15raplha sushi domain based modulokines Download PDFInfo
- Publication number
- WO2015018528A1 WO2015018528A1 PCT/EP2014/002181 EP2014002181W WO2015018528A1 WO 2015018528 A1 WO2015018528 A1 WO 2015018528A1 EP 2014002181 W EP2014002181 W EP 2014002181W WO 2015018528 A1 WO2015018528 A1 WO 2015018528A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- immunocytokine
- amino acid
- acid sequence
- antibody
- antagonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
Claims
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020167005428A KR102364523B1 (en) | 2013-08-08 | 2014-08-08 | IL-15 and IL-15R aplha sushi domain based modulokines |
CN201480052636.9A CN105612175B (en) | 2013-08-08 | 2014-08-08 | Modulators based on IL-15 and IL-15Rα sushi domains |
PL14761280T PL3030575T3 (en) | 2013-08-08 | 2014-08-08 | Il-15 and il-15r-alpha sushi domain based modulokines |
MX2016001555A MX2016001555A (en) | 2013-08-08 | 2014-08-08 | Il-15 and il-15raplha sushi domain based modulokines. |
AU2014304931A AU2014304931B2 (en) | 2013-08-08 | 2014-08-08 | IL-15 and IL-15Raplha sushi domain based modulokines |
PL18177685T PL3444271T3 (en) | 2013-08-08 | 2014-08-08 | Il-15 and il-15ralpha sushi domain based modulokines |
KR1020227004968A KR102564207B1 (en) | 2013-08-08 | 2014-08-08 | IL-15 and IL-15R aplha sushi domain based modulokines |
EP23191780.8A EP4269441A3 (en) | 2013-08-08 | 2014-08-08 | Il-15 and il-15ralpha sushi domain based on modulokines |
EP21200870.0A EP3995507B1 (en) | 2013-08-08 | 2014-08-08 | Il-15 and il-15ralpha sushi domain based on modulokines |
EP14761280.8A EP3030575B1 (en) | 2013-08-08 | 2014-08-08 | Il-15 and il-15r-alpha sushi domain based modulokines |
US14/910,475 US11273204B2 (en) | 2013-08-08 | 2014-08-08 | IL-15 and IL-15RAPLHA sushi domain based immunocytokines |
CA2919725A CA2919725C (en) | 2013-08-08 | 2014-08-08 | An il-15 and il-15r.aplha. sushi domain based modulokines |
SI201430898T SI3030575T1 (en) | 2013-08-08 | 2014-08-08 | Il-15 and il-15r-alpha sushi domain based modulokines |
DK14761280.8T DK3030575T3 (en) | 2013-08-08 | 2014-08-08 | IL-15 AND IL-15R-ALFA-SUSHI DOMAIN-BASED MODULOKINES |
ES14761280.8T ES2690046T3 (en) | 2013-08-08 | 2014-08-08 | Modulocins based on the sushi domain of IL-15 and IL-15r-alfa |
JP2016532265A JP6649254B2 (en) | 2013-08-08 | 2014-08-08 | Modulokines based on IL-15 and IL-15Rα sushi domains |
BR112016002614A BR112016002614B8 (en) | 2013-08-08 | 2014-08-08 | Immunocytokine and pharmaceutical composition |
EP18177685.7A EP3444271B1 (en) | 2013-08-08 | 2014-08-08 | Il-15 and il-15ralpha sushi domain based modulokines |
EA201690333A EA031080B1 (en) | 2013-08-08 | 2014-08-08 | IL-15 AND IL-15Rα SUSHI DOMAIN BASED MODULOKINES |
HRP20181472TT HRP20181472T1 (en) | 2013-08-08 | 2018-09-13 | Il-15 and il-15r-aplha sushi domain based modulokines |
US17/693,132 US20220193199A1 (en) | 2013-08-08 | 2022-03-11 | Il-15 and il-15ralpha sushi domain based modulokines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13003963 | 2013-08-08 | ||
EP13003963.9 | 2013-08-08 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/910,475 A-371-Of-International US11273204B2 (en) | 2013-08-08 | 2014-08-08 | IL-15 and IL-15RAPLHA sushi domain based immunocytokines |
US17/693,132 Continuation US20220193199A1 (en) | 2013-08-08 | 2022-03-11 | Il-15 and il-15ralpha sushi domain based modulokines |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015018528A1 true WO2015018528A1 (en) | 2015-02-12 |
WO2015018528A8 WO2015018528A8 (en) | 2016-04-07 |
Family
ID=48953308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2014/002181 WO2015018528A1 (en) | 2013-08-08 | 2014-08-08 | Il-15 and il-15raplha sushi domain based modulokines |
Country Status (18)
Country | Link |
---|---|
US (2) | US11273204B2 (en) |
EP (4) | EP3030575B1 (en) |
JP (2) | JP6649254B2 (en) |
KR (2) | KR102364523B1 (en) |
CN (1) | CN105612175B (en) |
AU (1) | AU2014304931B2 (en) |
BR (1) | BR112016002614B8 (en) |
CA (1) | CA2919725C (en) |
DK (2) | DK3030575T3 (en) |
EA (1) | EA031080B1 (en) |
ES (3) | ES2902589T3 (en) |
HR (3) | HRP20231437T1 (en) |
HU (2) | HUE064280T2 (en) |
MX (1) | MX2016001555A (en) |
PL (3) | PL3444271T3 (en) |
PT (2) | PT3444271T (en) |
SI (2) | SI3444271T1 (en) |
WO (1) | WO2015018528A1 (en) |
Cited By (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
US9512227B2 (en) | 2014-03-12 | 2016-12-06 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease |
WO2017046200A1 (en) * | 2015-09-16 | 2017-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases |
WO2017134302A3 (en) * | 2016-02-05 | 2017-09-28 | Orionis Biosciences Nv | Targeted therapeutic agents and uses thereof |
WO2018071918A1 (en) * | 2016-10-14 | 2018-04-19 | Xencor, Inc. | Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments |
WO2018184964A1 (en) | 2017-04-03 | 2018-10-11 | F. Hoffmann-La Roche Ag | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
EP3307783A4 (en) * | 2015-06-10 | 2018-10-24 | Emory University | Compositions and conjugates comprising an interleukin and polypeptides that specifically bind tgf-beta |
US10227410B2 (en) | 2015-12-07 | 2019-03-12 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and PSMA |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
US10251922B2 (en) | 2013-03-14 | 2019-04-09 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
US10287364B2 (en) | 2013-03-15 | 2019-05-14 | Xencor, Inc. | Heterodimeric proteins |
US10308913B2 (en) | 2005-12-02 | 2019-06-04 | Icahn School Of Medicine At Mount Sinai | Chimeric viruses presenting non-native surface proteins and uses thereof |
US10316088B2 (en) | 2016-06-28 | 2019-06-11 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
WO2019204655A1 (en) * | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
WO2019204646A1 (en) * | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains |
WO2019204592A1 (en) * | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
WO2019204665A1 (en) * | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
US10472427B2 (en) | 2013-01-14 | 2019-11-12 | Xencor, Inc. | Heterodimeric proteins |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US10544187B2 (en) | 2013-03-15 | 2020-01-28 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
WO2020132646A1 (en) * | 2018-12-20 | 2020-06-25 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains |
US10738133B2 (en) | 2013-01-14 | 2020-08-11 | Xencor, Inc. | Heterodimeric proteins |
US10787518B2 (en) | 2016-06-14 | 2020-09-29 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
US10808022B2 (en) | 2014-03-03 | 2020-10-20 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
WO2020234387A1 (en) | 2019-05-20 | 2020-11-26 | Cytune Pharma | IL-2/IL-15Rßy AGONIST DOSING REGIMENS FOR TREATING CANCER OR INFECTIOUS DISEASES |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
US10889653B2 (en) | 2014-11-26 | 2021-01-12 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
WO2021054867A1 (en) | 2019-09-19 | 2021-03-25 | Закрытое Акционерное Общество "Биокад" | IMMUNOCYTOKINE COMPRISING HETERODIMERIC PROTEIN COMPLEX BASED ON IL-15/IL-15Rα |
US10973917B2 (en) | 2016-05-18 | 2021-04-13 | Modernatx, Inc. | MRNA combination therapy for the treatment of cancer |
US10982006B2 (en) | 2018-04-04 | 2021-04-20 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
US10995141B2 (en) | 2019-04-19 | 2021-05-04 | ImmunoBrain Checkpoint, Inc. | Modified anti-PD-L1 antibody and methods and uses for treating a neurodegenerative disease |
WO2021099576A1 (en) * | 2019-11-21 | 2021-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel immunotherapies targeting pd-1 with anti-pd-1/il-15 immunocytokines |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US11058725B2 (en) | 2019-09-10 | 2021-07-13 | Obsidian Therapeutics, Inc. | CA2 compositions and methods for tunable regulation |
US11059876B2 (en) | 2018-02-28 | 2021-07-13 | Pfizer Inc. | IL-15 variants and uses thereof |
US11084863B2 (en) | 2017-06-30 | 2021-08-10 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains |
US11130810B2 (en) | 2015-10-02 | 2021-09-28 | Hoffmann-La Roche Inc. | Bispecific antibodies specific for PD1 and TIM3 |
EP3889183A1 (en) * | 2020-04-01 | 2021-10-06 | Pierre Fabre Medicament | A protein complex comprising an immunocytokine |
EP3740501A4 (en) * | 2018-01-18 | 2021-12-22 | Nant Holdings IP, LLC | Fusion protein extensions |
WO2022048563A1 (en) * | 2020-09-01 | 2022-03-10 | Wuxi Biologics (Shanghai) Co. Ltd. | Long-acting il-15 and uses thereof |
US11312770B2 (en) | 2017-11-08 | 2022-04-26 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
US11319355B2 (en) | 2017-12-19 | 2022-05-03 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
WO2022090202A1 (en) | 2020-10-26 | 2022-05-05 | Cytune Pharma | IL-2/IL-15RBβү AGONIST FOR TREATING NON-MELANOMA SKIN CANCER |
WO2022090203A1 (en) | 2020-10-26 | 2022-05-05 | Cytune Pharma | IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA |
US11352442B2 (en) | 2014-11-26 | 2022-06-07 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and CD38 |
US11358999B2 (en) | 2018-10-03 | 2022-06-14 | Xencor, Inc. | IL-12 heterodimeric Fc-fusion proteins |
US11377477B2 (en) | 2018-10-12 | 2022-07-05 | Xencor, Inc. | PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof |
US11389495B2 (en) | 2014-02-27 | 2022-07-19 | Merck Sharp & Dohme Llc | Combination method for treatment of cancer |
US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
US11472856B2 (en) | 2016-06-13 | 2022-10-18 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
US11472890B2 (en) | 2019-03-01 | 2022-10-18 | Xencor, Inc. | Heterodimeric antibodies that bind ENPP3 and CD3 |
US11498966B2 (en) | 2017-08-09 | 2022-11-15 | Orionis Biosciences Inc. | PD-1 and PD-L1 binding agents |
US11524033B2 (en) | 2017-09-05 | 2022-12-13 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
US11566072B2 (en) | 2017-08-09 | 2023-01-31 | Orionis Biosciences, Inc. | CD8 binding agents |
US11591401B2 (en) | 2020-08-19 | 2023-02-28 | Xencor, Inc. | Anti-CD28 compositions |
US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
EP4013796A4 (en) * | 2019-08-17 | 2023-08-02 | IGM Biosciences Inc. | Multimeric bispecific anti-cd123 binding molecules and uses thereof |
US11739144B2 (en) | 2021-03-09 | 2023-08-29 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and CLDN6 |
US11814423B2 (en) | 2013-03-15 | 2023-11-14 | Xencor, Inc. | Heterodimeric proteins |
US11840579B2 (en) | 2014-03-28 | 2023-12-12 | Xencor, Inc. | Bispecific antibodies that bind to CD38 and CD3 |
US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
US11932675B2 (en) | 2019-10-11 | 2024-03-19 | Genentech, Inc. | PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved properties |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11186641B2 (en) * | 2016-03-17 | 2021-11-30 | Oslo Universitetssykehus Hf | Fusion proteins targeting tumour associated macrophages for treating cancer |
KR102346336B1 (en) | 2017-04-05 | 2022-01-04 | 에프. 호프만-라 로슈 아게 | Bispecific antibodies that specifically bind to PD1 and LAG3 |
CN110478474B (en) * | 2019-08-21 | 2020-06-02 | 启辰生生物科技(珠海)有限公司 | Immunomodulator, vaccine, cell and application |
CN116574183A (en) * | 2019-08-22 | 2023-08-11 | 盛禾(中国)生物制药有限公司 | Multifunctional antibodies, their preparation and use |
CN110804588B (en) * | 2019-11-22 | 2020-09-01 | 启辰生生物科技(珠海)有限公司 | Composition for synergistically improving properties of T lymphocytes and use thereof |
WO2023086772A1 (en) | 2021-11-12 | 2023-05-19 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012175222A1 (en) * | 2011-06-24 | 2012-12-27 | Cytune | AN IL-15 AND IL-15Rα SUSHI DOMAIN BASED IMMUNOCYTOKINES |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5997856A (en) | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
US5108910A (en) | 1989-08-22 | 1992-04-28 | Immunex Corporation | DNA sequences encoding fusion proteins comprising GM-CSF and IL-3 |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
AU6703198A (en) | 1997-03-21 | 1998-10-20 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
EE05627B1 (en) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | Human monoclonal antibodies to CTLA-4 |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
ES2340745T3 (en) | 1998-12-23 | 2010-06-08 | Pfizer Inc. | HUMAN MONOCLONAL ANTIBODIES AGAINST CTLA-4. |
EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
IL149701A0 (en) | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
AR039067A1 (en) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
PL375144A1 (en) | 2002-07-30 | 2005-11-28 | Bristol-Myers Squibb Company | Humanized antibodies against human 4-1bb |
EP2330130B1 (en) | 2002-10-17 | 2014-08-27 | Genmab A/S | Human monoclonal antibodies against CD20 |
CN101899114A (en) | 2002-12-23 | 2010-12-01 | 惠氏公司 | Anti-PD-1 antibody and uses thereof |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
US20050136055A1 (en) | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
AU2004309275B2 (en) | 2003-12-25 | 2010-12-23 | Kyowa Kirin Co., Ltd. | Mutants of anti-CD40 antibody |
JP5744369B2 (en) | 2004-02-27 | 2015-07-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Specific IL-15 mutant with IL-15 binding site and agonist / antagonist activity for IL15-Rα |
EP1791868B1 (en) | 2004-07-01 | 2011-02-23 | Novo Nordisk A/S | Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use |
WO2006056875A1 (en) | 2004-11-29 | 2006-06-01 | Pharmacia & Upjohn Company Llc | Thiazepine oxazolidinones as antibacterial agents |
ES2432091T5 (en) | 2005-03-25 | 2022-03-18 | Gitr Inc | GITR binding molecules and uses thereof |
CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
MX2007014474A (en) | 2005-05-17 | 2008-02-07 | Univ Connecticut | Compositions and methods for immunomodulation in an organism. |
KR100694508B1 (en) | 2005-05-24 | 2007-03-13 | 울산대학교 산학협력단 | A composition comprising HBBK4 antibody for the treatment of cancer and the immunotherapic method for treating cancer using thereby |
CN104356236B (en) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | Human monoclonal antibodies to programmed death ligand 1(PD-L1) |
EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
TW200837081A (en) | 2006-11-15 | 2008-09-16 | Medarex Inc | Human monoclonal antibodies to BTLA and methods of use |
EP2133365B1 (en) | 2006-12-27 | 2017-05-17 | Emory University | Compositions and methods for the treatment of infections and tumors |
CA2690825C (en) | 2007-05-11 | 2019-02-12 | Altor Bioscience Corporation | Fusion molecules and il-15 variants |
EP3222634A1 (en) | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
NZ599338A (en) | 2007-06-27 | 2013-11-29 | Marinepolymer Tech Inc | Complexes of il-15 and il-15ralpha and uses thereof |
PT2594590E (en) | 2007-12-14 | 2015-01-14 | Bristol Myers Squibb Co | Method of producing binding molecules for the human ox40 receptor |
US8747847B2 (en) | 2008-02-11 | 2014-06-10 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Pd-1 binding proteins |
WO2009135031A1 (en) | 2008-04-30 | 2009-11-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Substituted il-15 |
AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
KR20110074850A (en) | 2008-08-25 | 2011-07-04 | 앰플리뮨, 인크. | Pd-1 antagonists and methods of use thereof |
WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
CA2736829C (en) | 2008-09-12 | 2018-02-27 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
US9181342B2 (en) | 2008-09-12 | 2015-11-10 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
AU2009296392B2 (en) | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
PE20120341A1 (en) | 2008-12-09 | 2012-04-24 | Genentech Inc | ANTI-PD-L1 ANTIBODIES AND ITS USE TO IMPROVE T-CELL FUNCTION |
WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
US20120064096A1 (en) | 2009-03-17 | 2012-03-15 | Universite De La Mediterranee | BTLA Antibodies and Uses Thereof |
EA201270228A1 (en) | 2009-07-31 | 2012-09-28 | Медарекс, Инк. | FULLY HUMAN ANTIBODIES TO BTLA |
CA2768965C (en) | 2009-08-14 | 2019-06-04 | George N. Pavlakis | Use of il-15 to increase thymic output and to treat lymphopenia |
US8709424B2 (en) | 2009-09-03 | 2014-04-29 | Merck Sharp & Dohme Corp. | Anti-GITR antibodies |
CA2791930A1 (en) | 2010-03-11 | 2011-09-15 | Kerry Louise Tyson | Pd-1 antibody |
MY171312A (en) | 2010-08-23 | 2019-10-08 | Univ Texas | Anti-ox40 antibodies and methods of using the same |
KR20140020228A (en) | 2010-09-21 | 2014-02-18 | 알토 바이오사이언스 코포레이션 | Multimeric il-15 soluble fusion molecules and methods of making and using same |
AU2011310887A1 (en) | 2010-09-29 | 2013-05-02 | Universite De Liege | Combination of an agonistic anti-CD40 monoclonal antibody or a CD40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis |
GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
TR201810298T4 (en) | 2011-03-31 | 2018-08-27 | Merck Sharp & Dohme | Stable formulations of antibodies against human programmed death receptor PD-1 and related treatments. |
WO2012145183A2 (en) | 2011-04-19 | 2012-10-26 | Pfizer Inc. | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
AU2012299421B2 (en) | 2011-08-23 | 2016-02-04 | Board Of Regents, The University Of Texas System | Anti-OX40 antibodies and methods of using the same |
GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
AU2013334610B2 (en) * | 2012-10-24 | 2018-09-13 | Novartis Ag | IL-15R alpha forms, cells expressing IL-15R alpha forms, and therapeutic uses of IL-15R alpha and IL-15/IL-15R alpha complexes |
DK2986312T3 (en) | 2013-04-19 | 2022-02-14 | Cytune Pharma | CYTOKINE DERIVATIVE TREATMENT WITH REDUCED VASCULAR MEDICAL SYNDROME |
US9580504B1 (en) | 2013-11-07 | 2017-02-28 | Curetech Ltd. | Pidilizumab monoclonal antibody therapy following stem cell transplantation |
JP2017509319A (en) | 2014-01-15 | 2017-04-06 | カドモン コーポレイション,リミティド ライアビリティ カンパニー | Immunomodulator |
-
2014
- 2014-08-08 US US14/910,475 patent/US11273204B2/en active Active
- 2014-08-08 SI SI201431932T patent/SI3444271T1/en unknown
- 2014-08-08 PL PL18177685T patent/PL3444271T3/en unknown
- 2014-08-08 EP EP14761280.8A patent/EP3030575B1/en active Active
- 2014-08-08 ES ES18177685T patent/ES2902589T3/en active Active
- 2014-08-08 JP JP2016532265A patent/JP6649254B2/en active Active
- 2014-08-08 DK DK14761280.8T patent/DK3030575T3/en active
- 2014-08-08 CN CN201480052636.9A patent/CN105612175B/en active Active
- 2014-08-08 SI SI201430898T patent/SI3030575T1/en unknown
- 2014-08-08 HR HRP20231437TT patent/HRP20231437T1/en unknown
- 2014-08-08 BR BR112016002614A patent/BR112016002614B8/en active IP Right Grant
- 2014-08-08 HU HUE21200870A patent/HUE064280T2/en unknown
- 2014-08-08 PL PL14761280T patent/PL3030575T3/en unknown
- 2014-08-08 EP EP21200870.0A patent/EP3995507B1/en active Active
- 2014-08-08 PT PT181776857T patent/PT3444271T/en unknown
- 2014-08-08 DK DK18177685.7T patent/DK3444271T3/en active
- 2014-08-08 PT PT14761280T patent/PT3030575T/en unknown
- 2014-08-08 HU HUE18177685A patent/HUE057598T2/en unknown
- 2014-08-08 AU AU2014304931A patent/AU2014304931B2/en active Active
- 2014-08-08 HR HRP20212023TT patent/HRP20212023T1/en unknown
- 2014-08-08 EA EA201690333A patent/EA031080B1/en unknown
- 2014-08-08 KR KR1020167005428A patent/KR102364523B1/en active IP Right Grant
- 2014-08-08 PL PL21200870.0T patent/PL3995507T3/en unknown
- 2014-08-08 MX MX2016001555A patent/MX2016001555A/en active IP Right Grant
- 2014-08-08 WO PCT/EP2014/002181 patent/WO2015018528A1/en active Application Filing
- 2014-08-08 EP EP23191780.8A patent/EP4269441A3/en active Pending
- 2014-08-08 ES ES21200870T patent/ES2963591T3/en active Active
- 2014-08-08 KR KR1020227004968A patent/KR102564207B1/en active IP Right Grant
- 2014-08-08 EP EP18177685.7A patent/EP3444271B1/en active Active
- 2014-08-08 ES ES14761280.8T patent/ES2690046T3/en active Active
- 2014-08-08 CA CA2919725A patent/CA2919725C/en active Active
-
2018
- 2018-09-13 HR HRP20181472TT patent/HRP20181472T1/en unknown
-
2020
- 2020-01-16 JP JP2020004814A patent/JP6951479B2/en active Active
-
2022
- 2022-03-11 US US17/693,132 patent/US20220193199A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012175222A1 (en) * | 2011-06-24 | 2012-12-27 | Cytune | AN IL-15 AND IL-15Rα SUSHI DOMAIN BASED IMMUNOCYTOKINES |
Non-Patent Citations (2)
Title |
---|
JASON C STEEL ET AL: "Interleukin-15 biology and its therapeutic implications in cancer", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 33, no. 1, January 2012 (2012-01-01), pages 35 - 41, XP028441944, ISSN: 0165-6147, [retrieved on 20110930], DOI: 10.1016/J.TIPS.2011.09.004 * |
W. E. CARSON: "Braking Bad: Blockade of Inhibitory Pathways Improves Interleukin-15 Therapy", CLINICAL CANCER RESEARCH, vol. 16, no. 24, 29 October 2010 (2010-10-29), pages 5917 - 5919, XP055150942, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-10-2658 * |
Cited By (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10308913B2 (en) | 2005-12-02 | 2019-06-04 | Icahn School Of Medicine At Mount Sinai | Chimeric viruses presenting non-native surface proteins and uses thereof |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
US10472427B2 (en) | 2013-01-14 | 2019-11-12 | Xencor, Inc. | Heterodimeric proteins |
US10738133B2 (en) | 2013-01-14 | 2020-08-11 | Xencor, Inc. | Heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US11718667B2 (en) | 2013-01-14 | 2023-08-08 | Xencor, Inc. | Optimized antibody variable regions |
US11634506B2 (en) | 2013-01-14 | 2023-04-25 | Xencor, Inc. | Heterodimeric proteins |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US10251922B2 (en) | 2013-03-14 | 2019-04-09 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
US11814423B2 (en) | 2013-03-15 | 2023-11-14 | Xencor, Inc. | Heterodimeric proteins |
US10544187B2 (en) | 2013-03-15 | 2020-01-28 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
US10287364B2 (en) | 2013-03-15 | 2019-05-14 | Xencor, Inc. | Heterodimeric proteins |
US11299554B2 (en) | 2013-03-15 | 2022-04-12 | Xencor, Inc. | Heterodimeric proteins |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US11389495B2 (en) | 2014-02-27 | 2022-07-19 | Merck Sharp & Dohme Llc | Combination method for treatment of cancer |
US10808022B2 (en) | 2014-03-03 | 2020-10-20 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
US9982049B2 (en) | 2014-03-12 | 2018-05-29 | Yeda Research And Development Co. Ltd. | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
US9982048B2 (en) | 2014-03-12 | 2018-05-29 | Yeda Research And Development Co. Ltd. | Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease |
US10214585B2 (en) | 2014-03-12 | 2019-02-26 | Yeda Research And Development Co., Ltd. | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US10144778B2 (en) | 2014-03-12 | 2018-12-04 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US10981989B2 (en) | 2014-03-12 | 2021-04-20 | Yeda Research And Development Co. Ltd. | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US11643464B2 (en) | 2014-03-12 | 2023-05-09 | Yeda Research and Develpment & Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of a retinal degeneration disorder |
US9982047B2 (en) | 2014-03-12 | 2018-05-29 | Yeda Research And Development Co. Ltd. | Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease |
US9982050B2 (en) | 2014-03-12 | 2018-05-29 | Yeda Research And Development Co. Ltd. | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
US9982051B2 (en) | 2014-03-12 | 2018-05-29 | Yeda Research And Development Co. Ltd. | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US10961309B2 (en) | 2014-03-12 | 2021-03-30 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
US11884728B2 (en) | 2014-03-12 | 2024-01-30 | Yeda Research And Development Co. Ltd. | Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis |
US11884727B2 (en) | 2014-03-12 | 2024-01-30 | Yeda Research And Development Co. Ltd. | Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis |
US9856318B2 (en) | 2014-03-12 | 2018-01-02 | Yeda Research And Development Co., Ltd. | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US11492405B2 (en) | 2014-03-12 | 2022-11-08 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the CNS |
US9534052B2 (en) | 2014-03-12 | 2017-01-03 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease |
US9512225B2 (en) | 2014-03-12 | 2016-12-06 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease |
US9512227B2 (en) | 2014-03-12 | 2016-12-06 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease |
US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US11840579B2 (en) | 2014-03-28 | 2023-12-12 | Xencor, Inc. | Bispecific antibodies that bind to CD38 and CD3 |
US11111315B2 (en) | 2014-11-26 | 2021-09-07 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
US11352442B2 (en) | 2014-11-26 | 2022-06-07 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and CD38 |
US11225528B2 (en) | 2014-11-26 | 2022-01-18 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
US11859011B2 (en) | 2014-11-26 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
US11945880B2 (en) | 2014-11-26 | 2024-04-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
US11673972B2 (en) | 2014-11-26 | 2023-06-13 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
US10889653B2 (en) | 2014-11-26 | 2021-01-12 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
US10913803B2 (en) | 2014-11-26 | 2021-02-09 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
US11091548B2 (en) | 2015-03-05 | 2021-08-17 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and Fc fusions |
EP3307783A4 (en) * | 2015-06-10 | 2018-10-24 | Emory University | Compositions and conjugates comprising an interleukin and polypeptides that specifically bind tgf-beta |
US10858452B2 (en) | 2015-09-16 | 2020-12-08 | Insitut National de la Sante et de la Recherche Medicale (INSERM) | Specific interleukin-15 (IL-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases |
WO2017046200A1 (en) * | 2015-09-16 | 2017-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases |
US11130810B2 (en) | 2015-10-02 | 2021-09-28 | Hoffmann-La Roche Inc. | Bispecific antibodies specific for PD1 and TIM3 |
US11623957B2 (en) | 2015-12-07 | 2023-04-11 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and PSMA |
US10227410B2 (en) | 2015-12-07 | 2019-03-12 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and PSMA |
US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
CN109071632B (en) * | 2016-02-05 | 2022-12-30 | 奥里尼斯生物科学私人有限公司 | Targeted therapeutic agents and uses thereof |
US11001631B2 (en) | 2016-02-05 | 2021-05-11 | Orionis Biosciences BV | Clec9A binding agents |
US10988538B2 (en) | 2016-02-05 | 2021-04-27 | Orionis Biosciences BV | Bispecific signaling agents and uses thereof |
US11236166B2 (en) | 2016-02-05 | 2022-02-01 | Orionis Biosciences BV | CD8 binding agents |
WO2017134302A3 (en) * | 2016-02-05 | 2017-09-28 | Orionis Biosciences Nv | Targeted therapeutic agents and uses thereof |
CN109071632A (en) * | 2016-02-05 | 2018-12-21 | 奥里尼斯生物科学公司 | Magnetic target therapy agent and application thereof |
US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
US10973917B2 (en) | 2016-05-18 | 2021-04-13 | Modernatx, Inc. | MRNA combination therapy for the treatment of cancer |
US11660341B2 (en) | 2016-05-18 | 2023-05-30 | Modernatx, Inc. | mRNA combination therapy for the treatment of cancer |
US11472856B2 (en) | 2016-06-13 | 2022-10-18 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
US11492407B2 (en) | 2016-06-14 | 2022-11-08 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
US10787518B2 (en) | 2016-06-14 | 2020-09-29 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
US11236170B2 (en) | 2016-06-14 | 2022-02-01 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
US11225521B2 (en) | 2016-06-28 | 2022-01-18 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
US10316088B2 (en) | 2016-06-28 | 2019-06-11 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
US11584794B2 (en) | 2016-10-14 | 2023-02-21 | Xencor, Inc. | Bispecific heterodimeric fusion proteins containing IL-15-IL-15Ralpha Fc-fusion proteins and immune checkpoint antibody fragments |
AU2017342559B2 (en) * | 2016-10-14 | 2022-03-24 | Xencor, Inc. | Bispecific heterodimeric fusion proteins containing IL-15/IL-15Ralpha Fc-fusion proteins and PD-1 antibody fragments |
WO2018071918A1 (en) * | 2016-10-14 | 2018-04-19 | Xencor, Inc. | Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments |
JP2019533444A (en) * | 2016-10-14 | 2019-11-21 | ゼンコア インコーポレイテッド | Bispecific heterodimeric fusion protein comprising a fragment of IL-15 / IL-15Ralpha Fc fusion protein and PD-1 antibody |
JP7273453B2 (en) | 2016-10-14 | 2023-05-15 | ゼンコア インコーポレイテッド | A bispecific heterodimeric fusion protein comprising an IL-15/IL-15R alpha Fc fusion protein and a fragment of a PD-1 antibody |
US10550185B2 (en) | 2016-10-14 | 2020-02-04 | Xencor, Inc. | Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragments |
US10501543B2 (en) | 2016-10-14 | 2019-12-10 | Xencor, Inc. | IL15/IL15Rα heterodimeric Fc-fusion proteins |
WO2018184964A1 (en) | 2017-04-03 | 2018-10-11 | F. Hoffmann-La Roche Ag | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
AU2018247765B2 (en) * | 2017-04-03 | 2023-11-23 | F. Hoffmann-La Roche Ag | Immunoconjugates of an Anti-PD-1 antibody with a mutant IL-2 or with IL-15 |
EP4201953A1 (en) * | 2017-04-03 | 2023-06-28 | F. Hoffmann-La Roche AG | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
EP3606946B1 (en) * | 2017-04-03 | 2022-08-24 | F. Hoffmann-La Roche AG | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
US11413331B2 (en) | 2017-04-03 | 2022-08-16 | Hoffmann-La Roche Inc. | Immunoconjugates |
US11084863B2 (en) | 2017-06-30 | 2021-08-10 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains |
US11498966B2 (en) | 2017-08-09 | 2022-11-15 | Orionis Biosciences Inc. | PD-1 and PD-L1 binding agents |
US11566072B2 (en) | 2017-08-09 | 2023-01-31 | Orionis Biosciences, Inc. | CD8 binding agents |
US11524033B2 (en) | 2017-09-05 | 2022-12-13 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
US11312770B2 (en) | 2017-11-08 | 2022-04-26 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
US11319355B2 (en) | 2017-12-19 | 2022-05-03 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
EP3740501A4 (en) * | 2018-01-18 | 2021-12-22 | Nant Holdings IP, LLC | Fusion protein extensions |
US11059876B2 (en) | 2018-02-28 | 2021-07-13 | Pfizer Inc. | IL-15 variants and uses thereof |
US10982006B2 (en) | 2018-04-04 | 2021-04-20 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
WO2019204655A1 (en) * | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
US11524991B2 (en) | 2018-04-18 | 2022-12-13 | Xencor, Inc. | PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof |
WO2019204646A1 (en) * | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains |
IL278090B1 (en) * | 2018-04-18 | 2024-03-01 | Xencor Inc | Il-15/il-15rα heterodimeric fc fusion proteins and uses thereof |
WO2019204592A1 (en) * | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
US11505595B2 (en) | 2018-04-18 | 2022-11-22 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains |
WO2019204665A1 (en) * | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
US11358999B2 (en) | 2018-10-03 | 2022-06-14 | Xencor, Inc. | IL-12 heterodimeric Fc-fusion proteins |
US11377477B2 (en) | 2018-10-12 | 2022-07-05 | Xencor, Inc. | PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof |
WO2020132646A1 (en) * | 2018-12-20 | 2020-06-25 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains |
US11618776B2 (en) | 2018-12-20 | 2023-04-04 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains |
US11472890B2 (en) | 2019-03-01 | 2022-10-18 | Xencor, Inc. | Heterodimeric antibodies that bind ENPP3 and CD3 |
US10995141B2 (en) | 2019-04-19 | 2021-05-04 | ImmunoBrain Checkpoint, Inc. | Modified anti-PD-L1 antibody and methods and uses for treating a neurodegenerative disease |
US11732046B2 (en) | 2019-04-19 | 2023-08-22 | ImmunoBrain Checkpoint, Inc. | Modified anti-PD-L1 antibody and methods and uses for treating a neurodegenerative disease |
WO2020234387A1 (en) | 2019-05-20 | 2020-11-26 | Cytune Pharma | IL-2/IL-15Rßy AGONIST DOSING REGIMENS FOR TREATING CANCER OR INFECTIOUS DISEASES |
KR20220012296A (en) | 2019-05-20 | 2022-02-03 | 싸이튠 파마 | IL-2/IL-15Rβγ agonist dosing regimen for treatment of cancer or infectious disease |
EP4013796A4 (en) * | 2019-08-17 | 2023-08-02 | IGM Biosciences Inc. | Multimeric bispecific anti-cd123 binding molecules and uses thereof |
US11058725B2 (en) | 2019-09-10 | 2021-07-13 | Obsidian Therapeutics, Inc. | CA2 compositions and methods for tunable regulation |
WO2021054867A1 (en) | 2019-09-19 | 2021-03-25 | Закрытое Акционерное Общество "Биокад" | IMMUNOCYTOKINE COMPRISING HETERODIMERIC PROTEIN COMPLEX BASED ON IL-15/IL-15Rα |
US11932675B2 (en) | 2019-10-11 | 2024-03-19 | Genentech, Inc. | PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved properties |
WO2021099576A1 (en) * | 2019-11-21 | 2021-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel immunotherapies targeting pd-1 with anti-pd-1/il-15 immunocytokines |
WO2021198490A1 (en) * | 2020-04-01 | 2021-10-07 | Pierre Fabre Medicament | A protein complex comprising an immunocytokine |
EP3889183A1 (en) * | 2020-04-01 | 2021-10-06 | Pierre Fabre Medicament | A protein complex comprising an immunocytokine |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
US11591401B2 (en) | 2020-08-19 | 2023-02-28 | Xencor, Inc. | Anti-CD28 compositions |
US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
WO2022048563A1 (en) * | 2020-09-01 | 2022-03-10 | Wuxi Biologics (Shanghai) Co. Ltd. | Long-acting il-15 and uses thereof |
KR20230096049A (en) | 2020-10-26 | 2023-06-29 | 싸이튠 파마 | IL-2/IL-15Rβγ agonists for the treatment of squamous cell carcinoma |
WO2022090202A1 (en) | 2020-10-26 | 2022-05-05 | Cytune Pharma | IL-2/IL-15RBβү AGONIST FOR TREATING NON-MELANOMA SKIN CANCER |
KR20230096047A (en) | 2020-10-26 | 2023-06-29 | 싸이튠 파마 | IL-2/IL-15Rβγ agonists for the treatment of non-melanoma skin cancer |
WO2022090203A1 (en) | 2020-10-26 | 2022-05-05 | Cytune Pharma | IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA |
US11739144B2 (en) | 2021-03-09 | 2023-08-29 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and CLDN6 |
US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220193199A1 (en) | Il-15 and il-15ralpha sushi domain based modulokines | |
US20220168395A1 (en) | Combined pharmaceutical composition | |
US20230071889A1 (en) | Bifunctional anti-pd-1/il-7 molecule |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14761280 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2919725 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/001555 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14910475 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2016532265 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016002614 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014761280 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2014304931 Country of ref document: AU Date of ref document: 20140808 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20167005428 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201690333 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 112016002614 Country of ref document: BR Kind code of ref document: A2 Effective date: 20160205 |